HONG KONG – Defying all expectations of an early announcement, biosimilar developers in China are unlikely to see any kind of regulatory framework in the near future.
HONG KONG – Defying all expectations of an early announcement, biosimilar developers in China are unlikely to see any kind of regulatory framework in the near future.
HONG KONG – China’s biopharmaceutical industry has been built around hundreds of dedicated zones that enjoy a series of benefits from municipal, provincial and central governments. These biotech parks, often independently managed, seek to attract multiple companies from both China and abroad.
HONG KONG – China’s biopharmaceutical industry has been built around hundreds of dedicated zones that enjoy a series of benefits from municipal, provincial and central governments.
